M&A Deal Summary

Travere Therapeutics Acquires Asklepion - Liquid Formulation Of Ursodeoxycholic Acid

On June 20, 2016, Travere Therapeutics acquired life science company Asklepion - Liquid Formulation Of Ursodeoxycholic Acid from Asklepion Pharmaceuticals

Acquisition Highlights
  • This is Travere Therapeutics’ 3rd transaction in the Life Science sector.
  • This is Travere Therapeutics’ 3rd transaction in the United States.

M&A Deal Summary

Date 2016-06-20
Target Asklepion - Liquid Formulation Of Ursodeoxycholic Acid
Sector Life Science
Buyer(s) Travere Therapeutics
Sellers(s) Asklepion Pharmaceuticals
Deal Type Divestiture

Target

Asklepion - Liquid Formulation Of Ursodeoxycholic Acid

United States
Asklepion - Liquid Formulation Of Ursodeoxycholic Acid also known as ursodiol or UDCA, ursodeoxycholic acid is a naturally occurring hydrophilic bile acid derived from cholesterol, which is indicated for the treatment of PBC and currently prescribed only in solid forms. Introducing a liquid formulation of ursodeoxycholic acid would provide healthcare professionals with a dosing alternative for patients who have difficulty swallowing tablets or capsules, and may facilitate increased compliance.

Search 214,503 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Travere Therapeutics

San Diego, California, United States

Category Company
Founded 2011
Sector Life Science
Employees385
Revenue 233M USD (2024)
DESCRIPTION

Travere Therapeutics is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. Travere Therapeutics was founded in 2011 and is based in San Diego, California.


DEAL STATS #
Overall 3 of 3
Sector: Life Science M&A 3 of 3
Type: Divestiture M&A Deals 1 of 1
Country: United States M&A 3 of 3
Year: 2016 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-02-12 Manchester Pharmaceuticals

Fort Collins, Colorado, United States

Manchester Pharmaceuticals is a privately-held specialty pharmaceutical company, is focused on the identification, development, and commercialization of therapeutic modalities to address the special needs of patients with ultra-rare diseases. Manchester markets Chenodal (chenodiol tablets) and Vecamyl® (mecamylamine tablets) in the U.S. Manchester's founders and management have extensive combined experience in the rare disease market.

Buy $63M

Seller(S) 1

SELLER

Asklepion Pharmaceuticals

Baltimore, Maryland, United States

Category Company
Founded 2006
Sector Life Science
DESCRIPTION

Asklepion Pharmaceuticals LLC is a biopharmaceutical company, focus on the development of treatments for rare pediatric diseases. Asklepion strives to channel the powers of science and biotechnology into therapies that are life-saving and to significantly improve the quality of life for sick children and anxious parents.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2016 M&A 1 of 1